Exagen (XGN): Director received 56K units

56K

Derivative units

Traded

Jun 9, 2026

Filed

Nov 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 17, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 17, 2026, Ana Hooker notified the Board of Directors (the “Board”) of Exagen Inc. (the “Company”) of her decision to resign as member of the Board, including all committees thereof, effective April 17, 2026 ("Effective Time").”
2. May 11, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
2. Sep 1, 2026InsiderCFO sold ~$149K of XGN shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Exagen

For Exagen, OQRO holds 9 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XGN page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Exagen

• SEC Form 4Nov 14, 2026
• SEC Form 4Nov 14, 2026
• SEC Schedule 13GNov 13, 2026
• SEC Schedule 13GNov 13, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 11, 2026

Everything OQRO holds on this company is on its XGN page.